Conference
162-LB: Cardiovascular Outcomes in People with Type 2 Diabetes and Acute Coronary Syndrome—The ELIXA Biomarker Study
Abstract
Adding novel protein biomarkers to routine clinical risk factors may identify people with type 2 diabetes and acute coronary syndrome who are at highest risk for cardiovascular (CV) outcomes and death.
Methods: Bio-banked baseline serum from 5128 of 6069 ELIXA (Evaluating Lixisenatide in Acute Coronary Syndrome) trial (NCT 01147250) participants was analyzed to identify independent risk factors for incident major adverse CV …
Authors
GERSTEIN HC; HESS S; CLAGGETT B; TARDIF J-C; PFEFFER MA
Volume
71
Publisher
American Diabetes Association
Publication Date
June 1, 2022
DOI
10.2337/db22-162-lb
Conference proceedings
Diabetes
Issue
Supplement_1
ISSN
0012-1797